Sally Bowden

Sally Bowden has an extensive work experience in various leadership roles in the biotechnology and healthcare industries. Sally is currently a Partner and Co-Founder at The P3 Acceleration Group, a position they have held since January 2023. Prior to this, they were the CEO of New Precedents, Inc. starting in 2009.

Sally has also held significant roles in regulatory affairs and quality management. Sally served as the VP of Regulatory Affairs and Quality at MeCo Diagnostics starting in November 2022, and as the Vice President of Quality and Regulatory Affairs at Codetta™ Bioscience starting in January 2022. Sally was the Head of Regulatory Affairs at RenalytixAI from an unknown start date to March 2023.

Additionally, Sally has been involved in volunteer work as President of Our Town of Cicero, A Mainstreet Organization since February 2023. Sally also worked as an Advisor at Kantaro Biosciences from February 2020 to March 2023.

Previously, Sally held leadership positions in quality and regulatory compliance at Roche Diagnostics, where they were the VP of Regulatory Compliance and Quality from April 2007 to July 2009, and at Ventana Medical Systems, where they were the VP of Corporate Quality and Competitive Excellence from June 2004 to April 2007. Sally also served as an Associate Professor at Indiana University-Purdue University School of Engineering and Technology from August 2000 to May 2004.

Throughout their career, Sally has demonstrated expertise in regulatory processes, quality management, and has been involved in academic teaching.

Sally Bowden's education history includes pursuing a Bachelor of Science degree in Industrial Engineering from Purdue University. Additionally, they obtained a Master's degree in Business Administration from Indiana Wesleyan University. The specific start and end years for their education are not provided.